Heart failure (HF) is a disabling condition involving complex vascular, neurohormonal and immune systems’ interactions. Osteoprotegerin (OPG), a bone-regulatory cytokine, has been suggested to play a key role in skeletal, vascular, and immune biology, with elevated levels observed in both experimental and clinical HF. In the present study we aimed to identify clinical OPG correlates and investigated whether elevated OPG, as a marker of HF vascular and immune activation, may interact with N-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of HF neurohormonal activation, thus synergistically increasing HF risk. We used a case-cohort study, nested within the European Prospective Investigation into Cancer and Nutrition-Potsdam, comprising 2647 participants including 252 incident HF cases identified during a mean follow-up of 8.2 ± 1.6 years. In both men and women significant positive associations were observed between OPG and age, smoking, prevalent diabetes, C-reactive protein, sex hormone-binding globulin, and additionally prevalent coronary heart disease and uric acid in men only. In women, OPG was furthermore positively related to hypertension and fetuin-A. After multivariable adjustment each doubling of OPG was associated with a 3.01-fold increased HF risk (95 % CI 1.49–6.06) in men. A significant interaction was observed between OPG and NT-proBNP. In men, a combination of high levels of both OPG and NT-proBNP, compared to a combination of low levels, was associated with an approximately fivefold increased HF risk. In women, no associations were observed. These findings suggest that, in men, the activation of different immune, neurohormonal, and vascular pathophysiological pathways may confer increased HF risk.
This is a preview of subscription content, log in to check access
We thank the Human Study Centre (HSC) of the German Institute of Human Nutrition Potsdam-Rehbrücke, namely the trustee and the examination unit for the collection, the data hub for the processing, and the participants for the provision of the data, the biobank for the processing of the biological samples and the head of the HSC, Manuela Bergmann, for the contribution to the study design and leading the underlying processes of data generation.
This work was supported by a grant from the Elsbeth Bonhoff Stiftung.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of the Medical Association of the State of Brandenburg and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51(6):627–33. doi:10.1016/j.jacc.2007.09.058.CrossRefPubMedGoogle Scholar
Lr P. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73:1–11.CrossRefGoogle Scholar
Boeing H, Wahrendorf J, Becker N. EPIC-Germany—a source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab. 1999;43(4):195–204.CrossRefPubMedGoogle Scholar
di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab. 2014;99(3):947–55. doi:10.1210/jc.2013-2963.CrossRefPubMedGoogle Scholar
Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Rev Esp Cardiol. 2005;58(9):1062–92.CrossRefPubMedGoogle Scholar
Jacobs S, Kroger J, Floegel A, Boeing H, Drogan D, Pischon T, et al. Evaluation of various biomarkers as potential mediators of the association between coffee consumption and incident type 2 diabetes in the EPIC-Potsdam Study. Am J Clin Nutr. 2014;100(3):891–900. doi:10.3945/ajcn.113.080317.CrossRefPubMedGoogle Scholar
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentralGoogle Scholar
Hopke PK, Liu C, Rubin DB. Multiple imputation for multivariate data with missing and below-threshold measurements: time-series concentrations of pollutants in the Arctic. Biometrics. 2001;57(1):22–33.CrossRefPubMedGoogle Scholar
di Giuseppe R, Kuhn T, Hirche F, Buijsse B, Dierkes J, Fritsche A, et al. Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study. Eur J Epidemiol. 2015;30(2):131–41. doi:10.1007/s10654-014-9982-4.CrossRefPubMedGoogle Scholar
Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol. 2006;64(6):652–8. doi:10.1111/j.1365-2265.2006.02522.x.CrossRefGoogle Scholar
Pascual-Figal DA, Tornel PL, Nicolas F, Sanchez-Mas J, Martinez MD, Gracia MR, et al. Sex hormone-binding globulin: a new marker of disease severity and prognosis in men with chronic heart failure. Rev Esp Cardiol. 2009;62(12):1381–7.CrossRefPubMedGoogle Scholar
Wang HH, Xiang GD. Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia. Mod Rheumatol. 2015;25(1):123–7. doi:10.3109/14397595.2014.926852.CrossRefPubMedGoogle Scholar
Rasul S, Ilhan A, Reiter MH, Todoric J, Farhan S, Esterbauer H, et al. Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. Clin Endocrinol. 2012;76(4):499–505. doi:10.1111/j.1365-2265.2011.04246.x.CrossRefGoogle Scholar
Aramburu-Bodas O, Garcia-Casado B, Salamanca-Bautista P, Guisado-Espartero ME, Arias-Jimenez JL, Barco-Sanchez A, et al. Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction. J Cardiovasc Med. 2015;16(6):438–43. doi:10.2459/JCM.0000000000000229.CrossRefGoogle Scholar
Bansal N, Zelnick L, Robinson-Cohen C, Hoofnagle AN, Ix JH, Lima JA, et al. Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001278. doi:10.1161/JAHA.114.001278.CrossRefPubMedPubMedCentralGoogle Scholar
Lutsey PL, Michos ED, Misialek JR, Pankow JS, Loehr L, Selvin E, et al. Race and vitamin d binding protein gene polymorphisms modify the association of 25-hydroxyvitamin d and incident heart failure: the ARIC (Atherosclerosis Risk in Communities) Study. JACC Heart Fail. 2015;3(5):347–56. doi:10.1016/j.jchf.2014.11.013.CrossRefPubMedPubMedCentralGoogle Scholar
Witberg G, Ayers CR, Turer AT, Lev E, Kornowski R, de Lemos J, et al. Relation of adiponectin to all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (from the Dallas Heart Study). Am J Cardiol. 2016;117(4):574–9. doi:10.1016/j.amjcard.2015.11.067.CrossRefPubMedGoogle Scholar
Jankowska EA, Ponikowski P. Sex hormone-binding globulin and heart failure: a passive carrier of steroid hormones or an active hormone itself? Rev Esp Cardiol. 2009;62(12):1353–5.CrossRefPubMedGoogle Scholar
Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab. 2012;97(4):E575–83. doi:10.1210/jc.2011-2836.CrossRefPubMedGoogle Scholar
Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 2014;85(5):1103–11. doi:10.1038/ki.2013.332.CrossRefPubMedGoogle Scholar
Fukumoto S. Vascular calcification—pathological mechanism and clinical application. Regulation of mineral metabolism and mineralization by FGF23. Clin Calcium. 2015;25(5):687–91.PubMedGoogle Scholar
Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H, et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail. 2007;9(4):357–63. doi:10.1016/j.ejheart.2006.10.015.CrossRefPubMedGoogle Scholar
Ahmed A, Nanda NC, Weaver MT, Allman RM, DeLong JF. Clinical correlates of isolated left ventricular diastolic dysfunction among hospitalized older heart failure patients. Am J Geriatr Cardiol. 2003;12(2):82–9.CrossRefPubMedGoogle Scholar